Robot-assisted Invasion-controlled Surgery Versus Traditional-open Surgery Against Metastatic Spinal Tumor
1 other identifier
interventional
60
1 country
1
Brief Summary
With significant advances in diagnostic imaging and systemic therapies for oncologic disease, spinal metastasis with neurological dysfunction and mechanical instability has become an indication for surgery. Even if traditional-open surgery was palliative, the treatment of spinal metastasis also carried significant surgical morbidity. Those high morbidity and complication rates may influence the quality of patients with a limited life expectancy. Invasion-controlled surgery was utilized with Robot-assisted surgery approach against symptomatic spinal metastasis. Increasing interest in the potential for improved consistency, complication reduction, and decreased length of hospitalization through robot utilization is evident from the rapid growth of publications seen in recent years. So, the investigators wish to evaluate the advantages of Robot-assisted Invasion-controlled Surgery compared with traditional-open surgery spinal surgery in patients with metastatic spinal cord compression.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Dec 2021
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 13, 2021
CompletedStudy Start
First participant enrolled
December 25, 2021
CompletedFirst Posted
Study publicly available on registry
December 30, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 10, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 10, 2023
CompletedDecember 30, 2021
December 1, 2021
12 months
December 13, 2021
December 25, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
operative bleeding
It is amount of blood lost during surgery, which is checked by the anesthesiologist and the surgical nurse.
Intraoperative
Secondary Outcomes (12)
operation time
Intraoperative
Intraoperative transfusion volume
Intraoperative
Intraoperative fluoroscopy dose
Intraoperative
VAS Scores
less than 2 years
Frankel Scores
less than 2 years
- +7 more secondary outcomes
Study Arms (2)
Robot-assisted Invasion-controlled Surgery
EXPERIMENTALTraditional-open Surgery
PLACEBO COMPARATORInterventions
The concept of invasion-controlled surgery (ICS) for spinal metastasis has been put forward against the spinal instability and neurological dysfunction of frail patients that might not allowed for radical traditional open surgery including improvements of multidisciplinary dynamic assessments, endovascular detachable balloon embolization, minimal-invasion by using expandable working tubes, percutaneous pedicle screws, and some accurate therapy. ICS could provide immediate stability, deformity correction, and recovery of neurological function.
This traditionally requires a midline incision, bilateral muscle strip, and multilevel laminectomy to provide adequate access and safe removal of the tumor.
Eligibility Criteria
You may qualify if:
- Confirmed diagnosis of spinal metastasis (previously confirmed diagnosis of lung cancer, liver cancer, prostate cancer, breast cancer, kidney cancer, digestive tract cancer, imaging indicated the presence of metastatic lesions in the spine)
- Patients with symptoms of spinal instability or nerve compression (SINS score of spinal instability ≥7, spinal nerve compression according to spinal cord injury Classification, grade A-D)
- Metastases are located in the thoracic and/or lumbar vertebrae
- The patient's expected survival was longer than 6 months
- The subjects or their legal representatives were able to understand the study purpose, demonstrate adequate compliance with the study protocol, and sign informed consent
You may not qualify if:
- He had previously operated on the same site
- Spontaneous multiple compression fractures of the spine;
- There is malformed osteitis (Paget's bone disease), osteomalacia, or other metabolic bone disease;
- here were developmental vertebral malformations or vertebral body and pedicle dysplasia in the spinal segment to be treated by surgery
- Presence of heart, lung, liver or kidney failure or other serious diseases (such as osteomyelitis, systemic infection, severe hemorrhagic disease, active disseminated intravascular coagulation, serious cardiovascular disease or myocardial infarction within 6 months prior to enrollment, cerebral infarction within 6 months prior to enrollment, severe psychiatric history)
- Pregnant or lactating women
- Participated in clinical trials of other drugs or medical devices within 3 months prior to enrollment
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Wei Xulead
Study Sites (1)
ChangZheng Hospital
Shanghai, Shanghai Municipality, 200001, China
Study Officials
- STUDY CHAIR
Jianru Xiao, Profession
Shanghai Changzheng Hospital
- STUDY DIRECTOR
Wei Xu, Profession
Shanghai Changzheng Hospital
- PRINCIPAL INVESTIGATOR
Bo Li, Profession
Shanghai Changzheng Hospital
- PRINCIPAL INVESTIGATOR
Pengru Wang, Profession
Shanghai Changzheng Hospital
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Clinical Professor
Study Record Dates
First Submitted
December 13, 2021
First Posted
December 30, 2021
Study Start
December 25, 2021
Primary Completion
December 10, 2022
Study Completion
December 10, 2023
Last Updated
December 30, 2021
Record last verified: 2021-12